Highly sulfated fucans for the treatment of fibrous adhesions
Inventors
SPRINGATE, CHRISTOPHER MICHAEL KEVIN • DASWANI, SAILESH HARESH
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11446326-B2
Publication Date
2022-09-20
Expiration Date
Abstract
A highly-sulfated modified fucan comprising a therapeutically effective, medically acceptable fucan in a composition comprising a sulfate to fucose molar ratio of greater than or equal to about 1.2, 1.81 or 1.9 and/or a sulfate to fucose plus galactose molar ratio of greater than or equal to about 1.1, 1.2 or 1.3.
Core Innovation
The invention relates to medically acceptable high-sulfate fucan compositions for inhibiting fibrous adhesions, including surgical adhesions, in an animal and in a patient. The compositions include a medically acceptable buffer or diluent and a therapeutically effective amount of a high-sulfate fucan having a sulfate to fucose molar ratio of between 1.2 and 1.9 and a sulfate to fucose plus galactose molar ratio of between 1.2 and 1.9.
The high-sulfate fucan is characterized by biochemical and physicochemical parameters to define the composition for treatment. Characterization includes sulfate-to-fucose molar ratio thresholds, sulfate-to-(fucose+galactose) molar ratio thresholds, sulfation level, total carbohydrate content, and viscosity, and can include molecular weight distribution measured by aqueous gel permeation chromatography and related standards.
The invention further provides methods for treating fibrous adhesions by selecting the defined high-sulfate fucan composition and administering a therapeutically effective amount to a wound, a target site, or a selected target site in an animal or patient. Administration is directed to wound sites and target sites, and in certain embodiments the target site is at least one of a lesion, an abrasion, or an injury site, including specified anatomical regions or tissues.
Claims Coverage
The patent includes independent method claims directed to treating fibrous adhesions in an animal and in a patient. Across these claims, the core inventive coverage is based on using a medically acceptable high-sulfate fucan composition with specified sulfate-to-fucose and sulfate-to-(fucose+galactose) molar ratio ranges, and administering it to a wound or selected target site, with an explicit therapeutically effective dose range in certain animal-treatment embodiments.
Sulfate ratio-defined high-sulfate fucan composition for adhesion inhibition treatment
Selecting a medically acceptable high-sulfate fucan composition to inhibit a fibrous adhesion, wherein the composition comprises a medically acceptable buffer or diluent and a therapeutically effective amount of a high-sulfate fucan having a sulfate to fucose molar ratio of between 1.2 and 1.9 and a sulfate to fucose plus galactose molar ratio of between 1.2 and 1.9.
Animal wound-site treatment with therapeutically effective dose range
Treating a fibrous adhesion in an animal by administering a therapeutically effective amount comprising a dosage range between 0.5 mg/kg and 50 mg/kg of the high-sulfate fucan to the site of a wound of the animal, using the medically acceptable high-sulfate fucan composition defined by the specified sulfate to fucose molar ratio and sulfate to fucose plus galactose molar ratio ranges.
Target-site administration in an animal using an agent and defined high-sulfate fucan composition
Treating a fibrous adhesion at a target site in an animal by selecting an agent for treating a fibrous adhesion and administering a therapeutically effective amount between about 0.04 mg/kg and 25 mg/kg of the high-sulfate fucan to the animal, wherein the administering comprises administering the therapeutically effective amount to the target site, and wherein the agent comprises a medically acceptable high-sulfate fucan composition with the specified sulfate to fucose molar ratio of between 1.2 and 1.9 and the specified sulfate to fucose plus galactose molar ratio of between 1.2 and 1.9.
Patient treatment by administration of composition with defined sulfate ratio ranges
Treating fibrous adhesions in a patient by administering a medically acceptable high-sulfate fucan composition comprising a medically acceptable buffer or diluent and a therapeutically effective amount of a high-sulfate fucan having a sulfate to fucose molar ratio of between 1.2 and 1.9 and a sulfate to fucose plus galactose molar ratio of between 1.2 and 1.9.
Patient identification of selected target site followed by administration
Treating a fibrous adhesion in a patient by identifying a selected target site in a patient comprising or susceptible to having the fibrous adhesion and then administering an agent for treating the fibrous adhesion, wherein the agent comprises a medically acceptable high-sulfate fucan composition comprising a medically acceptable buffer or diluent and a therapeutically effective amount of a high-sulfate fucan having a sulfate to fucose molar ratio of between 1.2 and 1.9 and a sulfate to fucose plus galactose molar ratio of between 1.2 and 1.9.
Direct medical composition administration to the selected target site in a patient
Treating a fibrous adhesion in a patient by identifying a selected target site in a patient comprising or susceptible to having the fibrous adhesion and then administering the medical composition to the selected target site in the patient, wherein the medical composition is a medically acceptable high-sulfate fucan composition comprising a medically acceptable buffer or diluent and a therapeutically effective amount of a high-sulfate fucan having a sulfate to fucose molar ratio of between 1.2 and 1.9 and a sulfate to fucose plus galactose molar ratio of between 1.2 and 1.9.
The claim coverage centers on treating fibrous adhesions by administering a medically acceptable high-sulfate fucan composition defined by sulfate to fucose and sulfate to fucose plus galactose molar ratio ranges between 1.2 and 1.9, with targeted administration to wound or target sites in animals and patients, and with an explicit therapeutically effective dose range in certain animal-treatment embodiments.
Stated Advantages
Inhibits the fibrous adhesion.
Documented Applications
Treating fibrous adhesions, including surgical adhesions, at a wound site in an animal or a patient.
Treating fibrous adhesions in a patient by administering a medically acceptable high-sulfate fucan composition to a selected target site.
Interested in licensing this patent?